Bioengineered probiotics to control SARS-CoV-2 infection

Bioengineered probiotics to control SARS-CoV-2 infection

Subhankar Chakraborty, Shantibhusan Senapati, Manisha Sethi, Jayalaxmi Dash

The outbreak of 2019 novel corona virus disease (COVID-19) is now a global public health crisis and declared as a pandemic. Several recent studies suggest that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein binds to human angiotensin-converting enzyme 2 (ACE2). The information obtained from these structural and biochemical studies provides a strong rationale to target SARS-CoV-2 spike protein and ACE2 interaction for developing therapeutics against this viral infection. Here, we propose to discuss the scope of bioengineered probiotics expressing human ACE2 as a novel therapeutic to control the viral outbreak.

2020

Probiotics, ACE2, SARS-CoV-2

DOI: 10.3897/rio.6.e54802

Research Ideas and Outcomes

Pensoft Publishers

Science